Jubilant Life Sciences presents 1,000 vials of Remdesivir to UP CM Yogi Adityanath

By: |
August 8, 2020 7:31 PM

The drug is being made available to over 1,000 hospitals providing COVID-19 treatment in India through the company's distribution network, Jubilant Life Sciences said in a statement.

"It gives us immense pleasure and satisfaction to present JUBI-R', the life-saving medicine, to Chief Minister of Uttar Pradesh Yogi Adityanath," Jubilant Life Sciences Chairman Shyam S Bhartia said.“It gives us immense pleasure and satisfaction to present JUBI-R’, the life-saving medicine, to Chief Minister of Uttar Pradesh Yogi Adityanath,” Jubilant Life Sciences Chairman Shyam S Bhartia said.

Drug firm Jubilant Life Sciences on Saturday said it has presented 1,000 vials of antiviral drug Remdesivir that it sells under the brand name ‘JUBI-R’ to Uttar Pradesh Chief Minister Yogi Adityanath.

The drug is being made available to over 1,000 hospitals providing COVID-19 treatment in India through the company’s distribution network, Jubilant Life Sciences said in a statement.

“Remdesivir is an effective medicine in the treatment of severe COVID-19 cases. In this critical situation, I am pleased that this medicine was made available by Jubilant in the quick time of two and a half months,” the company quoted Adityanath as saying.

“It gives us immense pleasure and satisfaction to present JUBI-R’, the life-saving medicine, to Chief Minister of Uttar Pradesh Yogi Adityanath,” Jubilant Life Sciences Chairman Shyam S Bhartia said.

The company is donating 1000 vials of JUBI-R through its CSR arm, the Jubilant Bhartia Foundation, he added.

In May 2020, Jubilant entered into a non-exclusive licensing agreement with Gilead Sciences, Inc., that granted it the right to register, manufacture and sell Gilead’s investigational drug remdesivir in 127 countries including India, the company said.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1London put on COVID-19 watchlist as coronavirus infection rate rises again across UK
2Coronavirus: AYUSH Ministry approves study to test impact of Vasa, Guduchi on management of COVID-19
3Delhi Deputy CM Sisodia administered plasma therapy treatment at Max hospital